Stephen Brand

US Patent:

6992060, Jan 31, 2006

Filed:

Jan 11, 2002

Appl. No.:

10/044048

Inventors:

Stephen J. Brand - Lincoln MA, US

Assignee:

Waratah Pharmaceuticals, Inc. - Verdun

International Classification:

A61K 38/16
A61K 38/18
C07K 14/485
C07K 14/595

US Classification:

514 2, 4241981, 514866, 530309, 530399

Abstract:

Compositions and methods are provided for achieving in vivo islet cell regeneration in subjects with preexisting diabetes. The methods comprise short term treatment with a composition having a gastrin/cholecystokinin receptor ligand and an EGF receptor ligand. Treatment with such a composition for a short term resulted in a prolonged period of increased insulin release, decreased fasting blood glucose, and improved glucose tolerance, the prolonged efficacy, the period being considered from the time of cessation of treatment.

US Patent:

7037504, May 2, 2006

Filed:

Oct 23, 2001

Appl. No.:

10/000840

Inventors:

Sheila G. Magil - Arlington MA, US
Susan D. Jones - Lexington MA, US
Gary W. Pace - Winchester MA, US
Stephen J. Brand - Lincoln MA, US

Assignee:

Waratah Pharmaceuticals, Inc. - Verdun

International Classification:

A61K 38/18
C07K 14/485
C12N 15/00

US Classification:

4241981, 530324, 435 691

Abstract:

Forms of epidermal growth factor that are resistant to proteolysis, and gene sequences encoding these forms and having codons optimized for usage by an industrial production organism, are provided.

US Patent:

7476388, Jan 13, 2009

Filed:

Nov 14, 2005

Appl. No.:

11/273615

Inventors:

Stephen J. Brand - Lincoln MA, US

Assignee:

Waratah Pharmaceuticals, Inc. - Verden

International Classification:

A61K 38/16
A61K 38/18
C07K 14/475
C07K 14/595

US Classification:

4241981, 4241841, 530300, 530350, 530399, 514 2, 514 12, 435810, 435975

Abstract:

Compositions and methods are provided for achieving in vivo islet cell regeneration in subjects with preexisting diabetes. The methods comprise short term treatment with a composition having a gastrin/cholecystokinin receptor ligand and an EGF receptor ligand. Treatment with such a composition for a short term resulted in a prolonged period of increased insulin release, decreased fasting blood glucose, and improved glucose tolerance, the prolonged efficacy, the period being considered from the time of cessation of treatment.

US Patent:

7560425, Jul 14, 2009

Filed:

Jun 9, 2003

Appl. No.:

10/517135

Inventors:

Stephen J. Brand - Lincoln MA, US
Antonio Cruz - Toronto, CA

Assignee:

Waratah Pharmaceuticals Inc. - Toronto, Ontario

International Classification:

A61K 38/00
A01N 45/00

US Classification:

514 2, 530300, 530309, 4241981, 524 26

Abstract:

Compositions and methods for islet neogenesis therapy comprising an EGF and a gastrin in combination with immune suppression, and for treating or preventing early stage diabetes with a gastrin/CCK receptor ligand and an immunosuppressant are provided.

US Patent:

20040023885, Feb 5, 2004

Filed:

Jun 9, 2003

Appl. No.:

10/457126

Inventors:

Stephen Brand - Lincoln MA, US
Antonio Cruz - Toronto, CA

International Classification:

A61K038/13
A61K038/17
A61K031/66
A61K031/573
A61K031/525
A61K031/522
A61K031/4745

US Classification:

514/012000, 514/011000, 514/263310, 514/109000, 514/171000, 514/291000, 514/251000, 514/469000, 514/669000

Abstract:

Compositions and methods for islet neogenesis therapy comprising an EGF and a gastrin in combination with immune suppression, and for treating or preventing early stage diabetes with a gastrin/CCK receptor ligand and an immunosuppressant are provided.

US Patent:

20040037818, Feb 26, 2004

Filed:

May 27, 2003

Appl. No.:

10/446612

Inventors:

Stephen Brand - Lincoln MA, US
Antonio Cruz - Toronto, CA
Alex Rabinovitch - Edmonton, CA
Wilma Suarez-Pinzon - Edmonton, CA

International Classification:

A61K048/00
C12N005/08

US Classification:

424/093210, 435/366000

Abstract:

Proliferating pancreatic islet cells obtained by the method of isolating a population of cells that preferably includes predominantly islet precursor cells that express one or more marker associated with an islet precursor cell and providing the precursor cells with one or more a pancreatic differentiation agent so that a population of cells is obtained that has a high proportion of cells with phenotypic characteristics of functional pancreatic islet -cells. Optionally, the precursor cells are pretreated by providing them with one or more cell expansion agent to increase the number of cells in the population prior to differentiation. The pancreatic differentiation agent composition comprises a gastrin/CCK receptor ligand, e.g., a gastrin, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The cell expansion agent composition comprises one or more epidermal growth factor (EGF) receptor ligand in an amount sufficient to stimulate proliferation of the precursor cells. The methods of treatment include transplanting either undifferentiated precursor cells and providing the pancreatic differentiation agent either alone or in combination with the cell expansion agent in situ, or transplanting the functional pancreatic islet -cells into the patient. The pancreatic islet -cells can be used for drug screening, and replenishing pancreatic function in the context of clinical treatment.

US Patent:

20040209801, Oct 21, 2004

Filed:

Oct 22, 2003

Appl. No.:

10/691123

Inventors:

Stephen Brand - Lincoln MA, US
Antonio Cruz - Toronto, CA
Aleksandra Pastrak - Toronto, CA
Yin Hew - Thornhill, CA

International Classification:

A61K038/17

US Classification:

514/012000

Abstract:

Compositions and methods are provided for islet neogenesis therapy comprising a member of a group of factors that complement a gastrin/CCK receptor ligand, with formulations, devices and methods for sustained release delivery and for local delivery to target organs.

US Patent:

20060189520, Aug 24, 2006

Filed:

Oct 22, 2003

Appl. No.:

10/532295

Inventors:

Stephen Brand - Lincoln MA, US
Antonio Cruz - Toronto, CA
Aleksandra Pastrak - Toronto, CA

International Classification:

A61K 38/22
A61K 38/19
A61K 38/18

US Classification:

514012000, 424085100

Abstract:

Compositions and methods are provided for islet neogenesis therapy comprising a member of a group of factors that complement a gastrin/CCK receptor ligand, with formulations, devices and methods for sustained release delivery and for local delivery to target organs.